HomeToday’s HighlightsAmgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Amgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Today’s Highlights April 10, 2019 Amgen and UDB Granted FDA Approval of Evenity™ Amgen (AMGN) and UCB Pharmaceuticals (This content is for paid subscribers. Please click here to subscribe or here to log in. Today’s Highlights Amgen (AMGN), UCB Pharmaceuticals (UCB) April 10, 2019 Tweet Pin It Other Articles Knowing What Cidara Therapeutics is Doing for the Seasonal Flu October 28, 2025 0 BridgeBio Pharma Reported Positive Phase 3 Results from FORTIFY the Phase 3 Pivotal Study of BBP-418 in People with Limb-Girdle Muscular Dystrophy Type 2I/R9 October 27, 2025 0 Why GRAL is Moving UP More Than Usual Today October 16, 2025 0 Akero Therapeutics Announced It Entered into a Definitive Agreement to be Acquired by Novo Nordisk October 9, 2025 0